Brief: Glycomimetics Completes Enrollment Of Phase 3 Registration Trial Evaluating Uproleselan In Acute Myeloid Leukemia (Aml)
15/11/2021 12:22
Nov 15 (Reuters) - GlycoMimetics Inc GLYC.O :
* GLYCOMIMETICS COMPLETES ENROLLMENT OF PHASE 3 REGISTRATION
TRIAL
EVALUATING LEAD CANDIDATE UPROLESELAN IN PATIENTS WITH RELAPSED
/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Source text for Eikon: ID:nBw1kQQga
Further company coverage: GLYC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering